Logo

Kite Reports sBLA Submission to the US FDA for Yescarta (axicabtagene ciloleucel) in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas

Share this

Kite Reports sBLA Submission to the US FDA for Yescarta (axicabtagene ciloleucel) in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas

Shots:

  • The sBLA submission is based on an ongoing P-II ZUMA-5 study assessing single infusion of Yescarta in ~160 patients (≥18 yrs.) with r/r indolent NHL of either FL or marginal zone lymphoma subtypes- prior treated with 2L therapies- including an anti-CD20 mAb combined with an alkylating agent
  • The 1EPs of the study is ORR as assessed by IRC while 2EPs include CRR- DOR- PFS- OS- safety and CAR T cell and cytokines levels
  • Yescarta is a CD19-directed genetically modified autologous T cell immunotherapy and has received the US FDA’s BT designation for indolent NHL. If approved- Yescarta would become the first CAR T cell therapy for this indication

­ Ref: Gilead | Image: Glassdoor

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions